Q/C Technologies (QCLS) Q4 2025 earnings summary

Executive summary

• Shifted strategic focus from pharmaceutical development to laser-based computing for blockchain, AI, and high-performance computing, leveraging an exclusive global license with LightSolver for photonic processing technology.

• Acquired LPU Holdings LLC, making it a wholly owned subsidiary and foundational to the new business direction.

• Evaluating divestiture or licensing of legacy pharmaceutical assets (Isomyosamine and Supera-CBD) to fund the new strategy.

Financial highlights

• No product revenue generated in 2025 or 2024; company remains pre-revenue with only investment income.

• Net loss attributable to common stockholders was $14.98M for 2025, improved from $27.16M in 2024.

• Operating expenses decreased 3.6% year-over-year to $9.81M in 2025.

• Cash and cash equivalents at year-end 2025 were $987K, with $14.8M in marketable securities.

• Working capital at year-end 2025 was $11.4M; stockholders’ equity was $21.75M.

Outlook and guidance

• Management believes current liquidity is sufficient for at least the next twelve months, but future capital raises may be needed for commercialization and growth.

• Near-term focus is on prototype development, benchmarking, and early commercialization of the qc-LPU100 system.

• No revenue expected in the near term; commercialization depends on successful validation and customer adoption.